Human medicines European public assessment report (EPAR): Kimmtrak, tebentafusp, Uveal Neoplasms, Date of authorisation: 01/04/2022, Revision: 1, Status: Authorised
Kimmtrak is a medicine used to treat adults with a type of eye cancer called ‘uveal melanoma’. It is used when the uveal melanoma cannot be removed by surgery or has spread to other parts of the body.
Uveal melanoma is rare, and Kimmtrak was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 February 2021.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
